ProCE Banner Activity

PROTECT: Adjuvant Pazopanib After Nephrectomy in Pts With Locally Advanced RCC

Slideset Download
Conference Coverage
Adjuvant pazopanib at 600 mg after nephrectomy did not prolong DFS compared with placebo in patients with locally advanced RCC.

Released: June 13, 2017

Expiration: June 12, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology